The trial includes dose-escalation and dose-expansion segments.

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas ...

About five million people worldwide have systemic lupus erythematosus (SLE), an autoimmune disease that damages organs and tissues throughout the body, including skin, joints, kidneys, heart, and ...